Equity options can act as an alternative to credit default swaps for detecting a company’s credit risk. Photo via Getty Images

Up until the 2007-2009 financial crisis, credit default swaps (CDS) were a predominant method for predicting the probability of corporate default. CDS function like insurance for loan assets — if an asset defaults, the bank who purchased the CDS would recoup their loss. Higher-risk assets usually have higher premiums, and in this way the price of a CDS indicates the probability of default.

When the housing market crashed in 2007, the CDS market crashed along with it when banks had to pay out more than they had expected. The CDS market is not expected to ever return to its previous high, leaving a void in market-driven estimates for determining an asset’s default probability.

To fill that void, a team of researchers including Rice Business Professor Robert Dittmar created an alternative method for measuring default risk: equity options data. The team found that equity options not only correlate with CDS data in terms of accurate prediction of default but also provide additional insights on what types of assets are more likely to default, and when they will default.

There are two types of options, a call option, which is essentially a bet that a stock’s price will be higher than a contracted value (the strike price) and a put option, which is a bet that a stock’s price will be less than a contracted value.

A put is often viewed as an insurance contract — if you hold a stock, but also a put option on it, you limit your loss on the stock if the stock price falls.

“What we are looking at is essentially how expensive put options get,” says Dittmar. “If the market thinks a company is likely to default, it expects that its stock value will fall (almost to zero). As a result, put options, which represent insurance against this loss become more expensive. We are looking at how these option prices change to see if they inform us about the probabilities of default.”

According to Dittmar and his team, this approach has several advantages. 1) There are more stocks with options than CDS. 2) The CDS market is drying up whereas the option market remains liquid. And 3) Because of the nature of an option contract, and the fact that in principle equity holders have the lowest claim on a company’s assets, this approach may allow investors to predict losses in case of default.

The team looked at CDS quotes on 276 firms between 2002 and 2017, focusing attention on entities that had quote data available on one-year credit default swaps. The 15-year sample enabled the researchers to analyze the money lost through defaults over a longer period of time, including the 2007-2009 financial crisis.

Using equity options data as a predictor of default led to some interesting insights. First, there are two components that investors in corporate bonds think about when weighing default risk — the probability of default and (should there be a default) how much of the bond’s principal they will get back (i.e., recovery rate). “What we see is that credit ratings imply different levels of default thresholds, which may mean that investors believe that there are differences in the amount that debt holders will lose in the case of default,” says Dittmar.

Second, option-implied default probabilities correlate to historical changes in the economy. Default probabilities are higher in bad economic times and for firms with poorer credit ratings and financial positions. Default spikes are more likely during times of economic turbulence, such as the financial crisis of 2007-2009, which correlated with the decline of the CDS market after an onslaught of debt defaults during the recession. Assets are less likely to default during times of economic expansion. Over the period of 2013-2017, forecasted losses through defaults hovered around 15%.

The research sample ends in 2017, and the paper was published in 2020, about a month after the start of the coronavirus pandemic. Since then, there have been unprecedented changes in the economy, and some economists are anticipating another recession in 2023. With such instability in the market, multiple methods of predicting losses should be especially relevant. This research suggests that the equity options market may provide additional ways of finding the probability of these losses.

------

This article originally ran on Rice Business Wisdom and was based on research from Robert Dittmar, professor of finance at the Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston VC funding nears $1B in first half of 2026, report says

by the numbers

Despite a weak second quarter, venture capital funding for Houston-area startups approached $1 billion in the first half of 2026, the region’s highest first-half total since 2022, according to the latest PitchBook-NVCA Venture Monitor.

This year’s first-half total of $962.4 million represented a nearly 8 percent increase over last year’s first-half total of $891.7 million. Dating back to 2016, this year’s first-half haul lags behind only 2021 and 2022 for the most first-half funding.

Houston’s year-over-year VC jump of 73 percent in the first quarter of 2026 more than made up for the year-over-year drop of 34 percent in the second quarter of 2026, according to the report.

Deal count tells a more encouraging story: Houston startups closed 102 deals in the first half, up from 93 a year earlier and the region’s busiest first half since 2022. However, the average deal size shrank, as no single funding source dominated the total.

Keep in mind that PitchBook and NVCA routinely revise quarterly numbers upward to reflect deals that were reported after a previous quarter’s data was published. So, in the case of Houston, numbers initially reported for the first quarter of 2026 may not match newly reported numbers.

Perhaps the most notable Houston-area deal announced in the first half of this year was Cart.com’s $180 million growth equity investment, led by Springcoast Partners. Cart.com is an e-commerce platform and logistics provider.

PitchBook-NVCA data shows Houston’s VC activity is growing modestly, delivering better numbers in the first half of 2026 versus 2024 and 2025, but it still sits below the highs of 2021 and 2022. This is one sign that so far in 2026, the national VC boom isn’t benefiting non-hub markets like Houston the way it’s boosting some hub markets, especially Silicon Valley and New York City.

Nationwide, AI dominated VC funding in the first half of this year. The sector made up 86 percent of VC from January through June. The report notes that the markets have still struggled to unlock IPOs, with SpaceX being the biggest exception, and few M&A deals outside health care have been significant.

14 climatech startups join Greentown Houston in first half of 2026

green team

Climatech incubator Greentown Labs reports that 14 startups have joined its Houston community so far this year.

The companies are among 30 new startups to have joined Greentown Houston and Greentown Boston in 2026. Four of the companies are headquartered in Houston.

The startups are working on a range of "hydrogen-powered heavy-duty transport to AI-driven grid interconnection," according to Greentown.

The local startups that joined Greentown Houston include:

  • Houston-based Focis AI, which transforms industrial laser scans into structured asset intelligence to automatically identify, classify and map components in refineries and plants
  • Houston-based Iron Lattice, which develops next-generation memory technology for AI and high-performance computing that improves energy efficiency, endurance and scalability while remaining compatible with existing semiconductor manufacturing
  • Houston-based Orbital Arc, which is developing a new ion engine designed to improve the efficiency and scalability of spacecraft propulsion from low Earth orbit to deep space
  • Houston-based Sustain Energy LLC, which delivers cleaner, lower-cost fuel to industrial customers in pipeline-absent, underserved markets, cutting their energy costs and emissions with no infrastructure investment on their end

Other startups from around the world joined the Houston incubator in the same time period, including:

  • Ankara-based AIS Field, which develops robotic, AI-assisted non-destructive inspection systems, including submersible tank and boiler crawlers
  • San Francisco-based Armada AI, which builds rapidly deployable modular and edge data centers that run on local, stranded, or renewable power
  • San Francisco-based Armeta, which turns complex engineering drawings and legacy documentation into structured, usable data
  • Pittsburgh-based Atlas Robotics, which develops a Physical AI platform that powers autonomous material-handling robots and AI-guided forklifts
  • Ghana-based Cocoa Potash, which transforms high-emissions agricultural waste from cocoa, coconut, and palm-nut into organic potash, fertilizer and renewable energy
  • Israel-based Criaterra, which produces low-carbon, cement-free building materials
  • Italy-based ETAK, which manufactures modular reactors that convert solid waste into clean syngas
  • Kenya-based FelixFusion, which uses its Felix platform to model every grid connection point, including capacity, upgrade costs, and constraints
  • San Diego-based Gemini Energy, which builds next-generation fuel cells for data-center power
  • Tokyo-based Hibot, which develops robotic systems for inspecting and maintaining infrastructure in hazardous, hard-to-access environments
  • Austin-based Sheetak, which designs and manufactures thermoelectric coolers, generators, and assemblies for solid-state cooling and energy harvesting
  • The Netherlands-based ToPerform, which makes AI-powered, non-intrusive fouling sensors that monitor pipelines around the clock and predict the optimal cleaning time

Another 16 startups joined Greentown's Boston incubator. See the full list of new members here.

More than 100 startups joined Greentown last year, according to an end-of-year reflection shared by Greentown CEO Georgina Campbell Flatter. Read more about them here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

$12M pharmaceutical manufacturing facility to be built in Sugar Land

coming soon

A nearly $12 million drug manufacturing facility is coming to Sugar Land.

City leaders in Sugar Land recently approved a $1.3 million performance-based incentive for DeliverIt Group, a Sugar Land-based provider of specialty pharmacy, infusion therapy and clinical care services, for the development of the 60,000-square-foot facility.

The facility, which will be registered with the U.S. Food and Drug Administration (FDA), will compound medication. The process of drug compounding combines, mixes or alters ingredients to create a medication tailored to a certain patient. A compounded drug is created when an FDA-approved drug can’t meet a patient’s needs.

The facility, which will employ 55 people, will expand DeliverIt’s offerings from specialty pharmacy and infusion services to advanced pharmaceutical manufacturing. In a press release, the City of Sugar Land says the facility reinforces the suburb’s status as a hub for life sciences and health care innovation.

DeliverIt, founded in 2010, already employs about 60 people.

The $1.3 million incentive, to be distributed over the course of 10 years, is being funded through the Sugar Land Development Corporation’s 4A sales tax program.

“The addition of a pharmaceutical manufacturing operation of this caliber reflects the type of targeted growth we want to see in Sugar Land,” Jennifer Alexander, business development manager for the City of Sugar Land, said in a news release. “Our focus on smart, strategic investment means supporting life sciences innovators in ways that maximize existing assets while driving long-term community prosperity.”

The current size of the U.S. drug-compounding market is estimated at $7.42 billion, and it’s projected to climb to $12.79 billion by 2035, according to Towards Healthcare Research and Consulting.

Drug compounding is gaining momentum due to increases in personalized medicine and personal treatment approaches, with growth being supported by aging populations and the rise of chronic illnesses, Towards Healthcare says.